THE DEAL, AT A GLANCE
3/4 reviewedBreye Therapeutics
01Medicine development
Checked 2026-10-01 · Review due 2026-10-08
Read supporting source ↗Breye Therapeutics is a clinical-stage…
02Who is involvedMission BioCapital and Novo Holdings co-led; Sound BioVentures and others participated as investors.Source-grounded · automated review · Explore ↗
03What happenedBreye Therapeutics raised Series A, announced 2026-09-29From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersFunding advances danegaptide toward mid-stage testing for earlier diabetic eye disease treatment.Interpretation · Explore ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Breye Therapeutics · Financing Record
Explore source-linked visual explanations for Breye Therapeutics. Unsupported claims are withheld while source review continues.
Record 13013 · Recorded date: 2026-09-29
Explore company records →